Archives of cardiovascular diseases · 2011
A prospective observational study of treatment practice patterns in acute coronary syndrome patients undergoing percutaneous coronary intervention in Europe.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ferrières Jean, Sartral Magali, Tcherny-Lessenot Stéphanie, Belger Mark, APTOR trial investigators
Аннотация
BACKGROUND: The AntiPlatelet Therapy Observational Registry (APTOR) was a prospective observational study of acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) in France, Spain, and the UK.
AIMS: To evaluate patterns of ACS healthcare use, focusing on APTOR results from France.
METHODS: Consecutive presenting ACS patients requiring PCI were recruited between January and August 2007. Treatments and outcomes were recorded from the qualifying ACS event to 12 months follow-up.
RESULTS: In France, qualifying diagnosis was unstable angina/non-ST-segment elevation myocardial infarction (UA/NSTEMI) in 255(53%) patients and ST-segment elevation myocardial infarction (STEMI) in 228(47%)patients. Ninety-six percent underwent PCI with stent implantation. Drug eluting stents were used less frequently in France(22%) than Spain (54%) or the UK (42%). In France, antiplatelets were more frequently received in the ambulance (21%); a 200-299mg aspirin-loading dose was most frequently received (50%) and more than a third of patients received a clopidogrel-loading dose of over 300mg (34%). At 12 months in France, 86% were still receiving aspirin, 75% clopidogrel, and 73% combination treatment.
CONCLUSION: There was considerable country-variation in ACS management. These results provide a benchmark of physician practice to compare with guidelines.
AIMS: To evaluate patterns of ACS healthcare use, focusing on APTOR results from France.
METHODS: Consecutive presenting ACS patients requiring PCI were recruited between January and August 2007. Treatments and outcomes were recorded from the qualifying ACS event to 12 months follow-up.
RESULTS: In France, qualifying diagnosis was unstable angina/non-ST-segment elevation myocardial infarction (UA/NSTEMI) in 255(53%) patients and ST-segment elevation myocardial infarction (STEMI) in 228(47%)patients. Ninety-six percent underwent PCI with stent implantation. Drug eluting stents were used less frequently in France(22%) than Spain (54%) or the UK (42%). In France, antiplatelets were more frequently received in the ambulance (21%); a 200-299mg aspirin-loading dose was most frequently received (50%) and more than a third of patients received a clopidogrel-loading dose of over 300mg (34%). At 12 months in France, 86% were still receiving aspirin, 75% clopidogrel, and 73% combination treatment.
CONCLUSION: There was considerable country-variation in ACS management. These results provide a benchmark of physician practice to compare with guidelines.
Предметные рубрики MeSH
Acute Coronary SyndromeAgedAngioplasty, Balloon, CoronaryDrug Administration ScheduleDrug Therapy, CombinationDrug UtilizationDrug-Eluting StentsEuropeFemaleGuideline AdherenceHumansLength of StayLogistic ModelsMaleMiddle AgedOdds RatioOutcome and Process Assessment, Health CarePlatelet Aggregation InhibitorsPractice Guidelines as TopicPractice Patterns, Physicians'Prospective StudiesRegistriesTime FactorsTreatment Outcome